TRIUMPH-4 is the first pivotal trial to confirm that the weight-loss signal seen in Phase 2 scales with longer exposure and higher doses, and it adds several new secondary findings that reshape how researchers think about 9 mg and 12 mg as working doses
Mechanism of action Melanotan II acts as a non-selective agonist of the melanocortin receptors MC1, MC3, MC4, and MC5
While Ozempic might have the current spotlight, its the lesser-known Wegovy that is actually FDA-approved specifically for weight loss
And often, those consequences do not fully show up until years later
"Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial." Obesity Pillars
These results are comparable to surgical interventions learn more about how Retatrutide compares to bariatric surgery in our detailed analysis